A Case of Refractory Lupus Nephritis Complicated by Psoriasis Vulgaris That Was Controlled With Secukinumab

Lupus. 2018 Jun;27(7):1202-1206. doi: 10.1177/0961203318762598. Epub 2018 Mar 9.


It has been reported that T helper 17 cells are involved in the pathogenesis of systemic lupus erythematosus, but there is no report on interleukin-17-targeted therapy. We report a case of a 62-year-old female who presented with psoriasis vulgaris and refractory lupus nephritis. Because her conditions were resistant to conventional treatment, and flow cytometry confirmed the proliferation of activated T helper 17 cells in peripheral blood, and examination of a renal biopsy tissue sample confirmed infiltration of numerous interleukin-17-positive lymphocytes to the renal interstitium, administration of the anti-interleukin-17A antibody secukinumab was initiated. After starting secukinumab the clinical and biological features were improved.

Keywords: SLE; anti-IL-17 antibody; lupus nephritis; psoriasis vulgaris; secukinumab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Female
  • Humans
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukin-17 / blood
  • Lupus Nephritis / complications*
  • Middle Aged
  • Psoriasis / drug therapy*


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • IL17A protein, human
  • Interleukin-17
  • secukinumab